Challenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAIc study baseline data

Bruno Linetzky, Brad Curtis, Gustavo Frechtel, Renan Montenegro Jr, Miguel Escalante Pulido, Oded Stempa, Janaina Martins de Lana, Juan José Gagliardino, Bruno Linetzky, Brad Curtis, Gustavo Frechtel, Renan Montenegro Jr, Miguel Escalante Pulido, Oded Stempa, Janaina Martins de Lana, Juan José Gagliardino

Abstract

Background: Poor glycemic control in patients with type 2 diabetes is commonly recorded worldwide; Latin America (LA) is not an exception. Barriers to intensifying insulin therapy and which barriers are most likely to negatively impact outcomes are not completely known. The objective was to identify barriers to insulin progression in individuals with type 2 diabetes mellitus (T2DM) in LA countries (Mexico, Brazil, and Argentina).

Methods: MOSAIc is a multinational, non-interventional, prospective, observational study aiming to identify the patient-, physician-, and healthcare-based factors affecting insulin intensification. Eligible patients were ≥18 years, had T2DM, and were treated with insulin for ≥3 months with/without oral antidiabetic drugs (OADs). Demographic, clinical, and psychosocial data were collected at baseline and regular intervals during the 24-month follow-up period. This paper however, focuses on baseline data analysis. The association between glycated hemoglobin (HbA1c) and selected covariates was assessed.

Results: A trend toward a higher level of HbA1c was observed in the LA versus non-LA population (8.40 ± 2.79 versus 8.18 ± 2.28; p ≤ 0.069). Significant differences were observed in clinical parameters, treatment patterns, and patient-reported outcomes in LA compared with the rest of the cohorts and between Mexico, Brazil, and Argentina. Higher number of insulin injections and lower number of OADs were used, whereas a lower level of knowledge and a higher level of diabetes-related distress were reported in LA. Covariates associated with HbA1c levels included age (-0.0129; p < 0.0001), number of OADs (0.0835; p = 0.0264), higher education level (-0.2261; p = 0.0101), healthy diet (-0.0555; p = 0.0083), self-monitoring blood glucose (-0.0512; p = 0.0033), hurried communication style in the process of care (0.1295; p = 0.0208), number of insulin injections (0.1616; p = 0.0088), adherence (-0.1939; p ≤ 0.0104), and not filling insulin prescription due to associated cost (0.2651; p = 0.0198).

Conclusion: MOSAIc baseline data showed that insulin intensification in LA is not optimal and identified several conditions that significantly affect attaining appropriate HbA1c values. Tailored public health strategies, including education, should be developed to overcome such barriers. Trial Registration NCT01400971.

Keywords: Diabetes education; Diabetes knowledge; Diabetes self-care management; Insulin treatment; Latin America; Observational study; Psychological impact; Quality of care; Type 2 diabetes.

References

    1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352(9131):837–853. doi: 10.1016/S0140-6736(98)07019-6.
    1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393. doi: 10.1056/NEJMoa021778.
    1. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr, Probstfield JL, Simons-Morton DG, Friedewald WT, Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. doi: 10.1056/NEJMoa0802743.
    1. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139. doi: 10.1056/NEJMoa0808431.
    1. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, MacMahon S, Marre M, Neal B, Patel A, Woodward M, Chalmers J, ADVANCE Collaborative Group. Cass A, Glasziou P, Harrap S, Lisheng L, Mancia G, Pillai A, Poulter N, Perkovic V, Travert F. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care. 2009;32:2068–2074. doi: 10.2337/dc09-0959.
    1. Escobedo J, Buitrón LV, Velasco MF, Ramírez JC, Hernández R, Macchia A, Pellegrini F, Schargrodsky H, Boissonnet C, Champagne BM, CARMELA Study Investigators High prevalence of diabetes and impaired fasting glucose in urban Latin America: the CARMELA Study. Diabet Med. 2009;26:864–871. doi: 10.1111/j.1464-5491.2009.02795.x.
    1. Lopez Stewart G, Tambascia M, Rosas Guzmán J, Etchegoyen F, Ortega Carrión J, Artemenko S. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. Rev Panam Salud Publica. 2007;22:12–20. doi: 10.1590/S1020-49892007000600002.
    1. Gagliardino JJ, Kleinebreil L, Colagiuri S, Flack J, Caporale JE, Siri F, Clark C., Jr Comparison of clinical-metabolic monitoring and outcomes and coronary risk status in people with type 2 diabetes from Australia, France and Latin America. Diabetes Res Clin Pract. 2010;88:7–13. doi: 10.1016/j.diabres.2009.12.024.
    1. Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SR, Hancu N, Ilkova H, Ramachandran A, Aschner P, IDMPS Investigators Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS) Diabetes Care. 2009;32:227–233. doi: 10.2337/dc08-0435.
    1. Shah S, Yang W, Hasan MI, Malek R, Molskov Bech O, Home P. Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve) Diabetes Technol Ther. 2013;15:954–963. doi: 10.1089/dia.2013.0074.
    1. Commendatore V, Dieuzeide G, Faingold C, Fuente G, Luján D, Aschner P, Lapertosa S, Villena Chávez J, Elgart J, Gagliardino JJ, DIFAR Academic Committee Registry of people with diabetes in three Latin American countries: a suitable approach to evaluate the quality of health care provided to people with type 2 diabetes. Int J Clin Pract. 2013;67:1261–1266. doi: 10.1111/ijcp.12208.
    1. Brown JB, Nichols GA. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care. 2003;9:213–217.
    1. Escalante M, Gagliardino JJ, Guzman JR, Tschiedel B. Call-to-action: timely and appropriate treatment for people with type 2 diabetes in Latin America. Diabetes Res Clin Pract. 2014;104:343–352. doi: 10.1016/j.diabres.2014.01.004.
    1. Grant RW, Buse JB, Meigs JB, University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team Quality of diabetes care in US Academic Medical Centers: low rates of medical regimen change. Diabetes Care. 2005;28:337–442. doi: 10.2337/diacare.28.2.337.
    1. Gough S, Frandsen KB, Toft AD. Failure of insulin monotherapy in patients with type 2 diabetes: a population-based study. Diabetes. 2006;55(Suppl. 1):A114.
    1. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57:455–460.
    1. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, INITIATE Study Group Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265. doi: 10.2337/diacare.28.2.260.
    1. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK, 4-T Study Group Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747. doi: 10.1056/NEJMoa0905479.
    1. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L, International DAWN Advisory Panel Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–2679. doi: 10.2337/diacare.28.11.2673.
    1. Philis-Tsimikas A. Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. Am J Med. 2013;126(9 Suppl 1):S21–S27. doi: 10.1016/j.amjmed.2013.06.010.
    1. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM. 2000;93:369–374. doi: 10.1093/qjmed/93.6.369.
    1. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med. 2013;30:512–524. doi: 10.1111/dme.12128.
    1. McEwen LN, Bilik D, Johnson SL, Halter JB, Karter AJ, Mangione CM, Subramanian U, Waitzfelder B, Crosson JC, Herman WH. Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD) Diabetes Care. 2009;32:971–976. doi: 10.2337/dc08-1911.
    1. Polinski JM, Curtis BH, Seeger JD, Choudhry NK, Zagar A, Shrank WH. Rationale and design of the multinational observational study assessing insulin use: the MOSAIc study. BMC Endocr Disord. 2012;12:20. doi: 10.1186/1472-6823-12-20.
    1. Fitzgerald JT, Funnell MM, Hess GE, Barr PA, Anderson RM, Hiss RG, Davis WK. The reliability and validity of a brief diabetes knowledge test. Diabetes Care. 1998;21:706–710. doi: 10.2337/diacare.21.5.706.
    1. Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, Jackson RA. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care. 2005;28:626–631. doi: 10.2337/diacare.28.3.626.
    1. Stewart AL, Napoles-Springer AM, Gregorich SE, Santoyo-Olsson J. Interpersonal processes of care survey: patient-reported measures for diverse groups. Health Serv Res. 2007;42(3 Pt 1):1235–1256. doi: 10.1111/j.1475-6773.2006.00637.x.
    1. Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care. 2000;23:943–950. doi: 10.2337/diacare.23.7.943.
    1. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res. 2011;20:40–49. doi: 10.1002/mpr.329.
    1. Ali MK, Bullard KM, Gregg EW. Achievement of goals in US Diabetes Care, 1999–2010. N Engl J Med. 2013;369:287–288. doi: 10.1056/NEJMc1306652.
    1. Guzman JR, Lyra R, Aguilar-Salinas CA, Cavalcanti S, Escaño F, Tambasia M, Duarte E, ALAD Consensus Group Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association. Rev Panam Salud Publica. 2010;28:463–471. doi: 10.1590/S1020-49892010001200008.
    1. Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ping L, Ye J, Rosenstock J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L) Diabetes Care. 2013;36:2489–2496. doi: 10.2337/dc12-2454.
    1. Yki-Jarvinen H, Rosenstock J, Durán-Garcia S, Pinnetti S, Bhattacharya S, Thiemann S, Patel S, Woerle HJ. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a 52-week randomized, double-blind study. Diabetes Care. 2013;36:3875–3881. doi: 10.2337/dc12-2718.
    1. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103–112. doi: 10.7326/0003-4819-154-2-201101180-00300.
    1. Liu L, Lou Q, Guo X, Yuan L, Shen L, Sun Z, Zhao F, Dai X, Huang J, Yang H, Mordes JP, Chinese Diabetes Education Status Survey Study Group Management status and its predictive factors in patients with type 2 diabetes in China: a Nationwide Multicenter Study. Diabetes Metab Res Rev. 2015;31:811–816. doi: 10.1002/dmrr.2757.
    1. Teoh H, Braga MF, Casanova A, Drouin D, Goodman SG, Harris SB, Langer A, Tan MK, Ur E, Yan AT, Zinman B, Leiter LA, T2DM QUERI Investigators Patient age, ethnicity, medical history, and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets: time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI) Diabetes Care. 2010;33:2558–2560. doi: 10.2337/dc10-0440.
    1. Lo-Ciganic WH, Donohue JM, Thorpe JM, Perera S, Thorpe CT, Marcum ZA, Gellad WF. Using machine learning to examine medication adherence thresholds and risk of hospitalization. Med Care. 2015;53:720–728. doi: 10.1097/MLR.0000000000000394.
    1. Williams J, Steers WN, Ettner SL, Mangione CM, Duru OK. Cost-related nonadherence by medication type among Medicare Part D beneficiaries with diabetes. Med Care. 2013;51:193–198. doi: 10.1097/MLR.0b013e318270dc52.
    1. Gagliardino JJ, Etchegoyen G, PENDID-LA Research Group A model educational program for people with type 2 diabetes: a cooperative Latin American implementation study (PEDNID-LA) Diabetes Care. 2001;24:1001–1007. doi: 10.2337/diacare.24.6.1001.
    1. Ellis SE, Speroff T, Dittus RS, Brown A, Pichert JW, Elasy TA. Diabetes patient counseling: a meta-analysis and meta-regression. Patient Educ Couns. 2005;52:97–105. doi: 10.1016/S0738-3991(03)00016-8.
    1. Wagner EH, Grothaus LC, Sandhu N, Galvin MS, McGregor M, Artz K, Coleman EA. Chronic care clinics for diabetes in primary care: a system-wide randomized trial. Diabetes Care. 2001;24:695–700. doi: 10.2337/diacare.24.4.695.
    1. Brownson CA, Hoerger TJ, Fisher EB, Kilpatrick KE. Cost-effectiveness of diabetes self-management programs in community primary care settings. Diabetes Educ. 2009;35:761–769. doi: 10.1177/0145721709340931.
    1. Gagliardino JJ, Lapertosa S, Pfirter G, Villagra M, Caporale JE, Gonzalez CD, Elgart J, González L, Cernadas C, Rucci E, Clark C, Jr, PRODIACOR Clinical, metabolic and psychological outcomes and treatment costs of a prospective randomized trial based on different educational strategies to improve diabetes care (PRODIACOR) Diabet Med. 2013;30:1102–1111. doi: 10.1111/dme.12230.
    1. Trento M, Gamba S, Gentile L, Grassi G, Miselli V, Morone G, Passera P, Tonutti L, Tomalino M, Bondonio P, Cavallo F, Porta M, ROMEO Investigators Rethink Organization to iMprove Education and Outcomes (ROMEO): a multicenter randomized trial of lifestyle intervention by group care to manage type 2 diabetes. Diabetes Care. 2010;33:745–747. doi: 10.2337/dc09-2024.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться